-
Posted by
Two Blokes Jun 30 -
Filed in
Stock
-
4 views
hVIVO PLC (AIM:HVO) said it had completed a key role in a large-scale clinical trial of a new flu prevention drug that showed strong results, marking another milestone for the specialist research organisation. The London-based company, which runs clinical trials on behalf of drug developers, helped recruit participants and provided laboratory analysis for a Phase 2b field study of CD388, an injectable treatment being developed by Cidara Therapeutics as a preventative option for seasonal influenza.
